Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration aims to jointly discover and develop new therapeutics based on small interfering RNA (siRNA) technology to address unmet medical needs in the treatment of liver and metabolic diseases. Financial details of the partnership were not disclosed.
Sciwind Biosciences: Company Overview
Sciwind Biosciences is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases. The company’s product pipeline includes potentially first-in-class and best-in-class drug candidates. Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and has identified a series of drug candidates based on these core platform technologies.
SynerK Inc.: Company Overview
SynerK Inc. is a biopharmaceutical company specializing in the development of RNA-targeted therapeutics. The company operates three R&D centers located in Boston, Massachusetts, in the US, and in Suzhou and Beijing in China. SynerK’s founders are seasoned industry experts in the discovery and development of RNA therapeutics. SynerK aims to build a world-class RNA-targeted therapeutics company to address diseases that have been difficult or impossible to treat through traditional approaches.
Future Outlook
The partnership between Sciwind Biosciences and SynerK marks a significant step in advancing the development of siRNA-based therapeutics for liver and metabolic diseases. By combining their expertise and proprietary technologies, the collaboration aims to bring innovative treatments to patients with unmet medical needs.-Fineline Info & Tech
